Dome JS, Mullen EA, Dix DB, et al. Impact of the first generation of Children’s Oncology Group clinical trials on clinical practice for Wilms tumor. J Natl Compr Canc Netw 2021;19:978–985.

• Crossref
• PubMed
Dome JS, Mullen EA, Dix DB, Impact of the first generation of Children’s Oncology Group clinical trials on clinical practice for Wilms tumor. J Natl Compr Canc Netw 2021;19:978–985.3441670510.6004/jnccn.2021.7070)| false
• Search Google Scholar
• Export Citation

Dix DB, Seibel NL, Chi YY, et al. Treatment of stage IV favorable histology Wilms tumor with lung metastases: a report from the Children’s Oncology Group AREN0533 study. J Clin Oncol 2018;36:1564–1570.

• Crossref
• PubMed
Dix DB, Seibel NL, Chi YY, Treatment of stage IV favorable histology Wilms tumor with lung metastases: a report from the Children’s Oncology Group AREN0533 study. J Clin Oncol 2018;36:1564–1570.10.1200/JCO.2017.77.193129659330)| false
• Search Google Scholar
• Export Citation

Grundy PE, Green DM, Dirks AC, et al. Clinical significance of pulmonary nodules detected by CT and not CXR in patients treated for favorable histology Wilms tumor on national Wilms tumor studies-4 and -5: a report from the Children’s Oncology Group. Pediatr Blood Cancer 2012;59:631–635.

• Crossref
• PubMed
Grundy PE, Green DM, Dirks AC, Clinical significance of pulmonary nodules detected by CT and not CXR in patients treated for favorable histology Wilms tumor on national Wilms tumor studies-4 and -5: a report from the Children’s Oncology Group. Pediatr Blood Cancer 2012;59:631–635.10.1002/pbc.24123)| false
• Search Google Scholar
• Export Citation

Dix DB, Fernandez CV, Chi YY, et al. Augmentation of therapy for combined loss of heterozygosity of chromosomes 1p and 16q in favorable histology Wilms tumor: a Children’s Oncology Group AREN0532 and AREN0533 study report. J Clin Oncol 2019;37:2769–2777.

• Crossref
• PubMed
Dix DB, Fernandez CV, Chi YY, Augmentation of therapy for combined loss of heterozygosity of chromosomes 1p and 16q in favorable histology Wilms tumor: a Children’s Oncology Group AREN0532 and AREN0533 study report. J Clin Oncol 2019;37:2769–2777.3144946810.1200/JCO.18.01972)| false
• Search Google Scholar
• Export Citation

Ehrlich PF, Ferrer FA, Ritchey ML, et al. Hepatic metastasis at diagnosis in patients with Wilms tumor is not an independent adverse prognostic factor for stage IV Wilms tumor: a report from the Children’s Oncology Group/National Wilms Tumor Study Group. Ann Surg 2009;250:642–648.

• Crossref
• PubMed
Ehrlich PF, Ferrer FA, Ritchey ML, Hepatic metastasis at diagnosis in patients with Wilms tumor is not an independent adverse prognostic factor for stage IV Wilms tumor: a report from the Children’s Oncology Group/National Wilms Tumor Study Group. Ann Surg 2009;250:642–648.1973024110.1097/SLA.0b013e3181b76f20)| false
• Search Google Scholar
• Export Citation

Fernandez CV, Mullen EA, Chi YY, et al. Outcome and prognostic factors in stage III favorable-histology Wilms tumor: a report from the Children’s Oncology Group study AREN0532. J Clin Oncol 2019;37:2710

• PubMed
Fernandez CV, Mullen EA, Chi YY, Outcome and prognostic factors in stage III favorable-histology Wilms tumor: a report from the Children’s Oncology Group study AREN0532. J Clin Oncol 2019;37:2710)| false
• Search Google Scholar
• Export Citation

Fernandez CV, Mullen EA, Chi YY, et al. Outcome and prognostic factors in stage III favorable-histology Wilms tumor: a report from the Children’s Oncology Group study AREN0532. J Clin Oncol 2018;36:254–261.

• Crossref
• PubMed
Fernandez CV, Mullen EA, Chi YY, Outcome and prognostic factors in stage III favorable-histology Wilms tumor: a report from the Children’s Oncology Group study AREN0532. J Clin Oncol 2018;36:254–261.10.1200/JCO.2017.73.7999)| false
• Search Google Scholar
• Export Citation